Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: Correlations with markers of inflammation and joint destruction

Arthritis and Rheumatism

Volumn 41, Issue 6, 1998, Pages 1083-1089

  Jouvenne, Patricia ^a   Vannier, Edouard ^b   Dinarello, Charles A ^b   Miossec, Pierre ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE;

ADULT; AGED; ARTICLE; CHRONIC ARTHRITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOASSAY; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; ARTHRITIS; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; RECEPTORS, INTERLEUKIN-1; SOLUBILITY;

EID: 0031781517     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199806)41:6<1083::AID-ART15>3.0.CO;2-9     Document Type: Article

References (43)

1. Miossec P. Role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 1987;5:305-8.
2. Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992;31:653-61.
3. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
4. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
5. Bendtzen K, Svenson M, Jonsson V, Hippe E. Autoantibodies to cytokines: friends or foes? Immunol Today 1990;11:167-9.
6. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993; 54:167-227.
7. Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993;261:472-5.
8. Seckinger P, Lowenthal JW, Williamson K, Dayer J-M, MacDonald HR. A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol 1987;139:1546-9.
9. Carter DB, Deibel MR Jr, Dunn CJ, Tomich C-SC, Laborde AL, Slightom JL, et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990;314:633-7.
10. Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A 1984;81:7907-11.
11. Chomarat P, Vannier E, Dechanet J, Rissoan M-C, Banchereau J, Dinarello CA, et al. The balance of IL-1 receptor antagonist/IL-1β in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 1995;154:1432-9.
12. Firestein GS, Boyle DL, Yu C, Paine MM, Whisenand TD, Zvaifler NJ, et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994;37:644-52.
13. Koch AE, Kunkel SL, Chensue SW, Haines GK, Strieter RM. Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. Clin Immunol Immunopathol 1992;65:23-9.
14. Deleuran BW, Chu CQ, Field M, Brennan FM, Katsikis P, Feldmann M, et al. Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 1992;31:801-9.
15. Malyak M, Swaney RE, Arend WP. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies: potential contribution from synovial fluid neutrophils. Arthritis Rheum 1993;36:781-9.
16. Slack J, McMahan CJ, Waugh S, Schooley K, Spriggs MK, Sims JE, et al. Independent binding of interleukin-1 alpha and interleukin-1 beta to type I and type II interleukin-1 receptors. J Biol Chem 1993;268:2513-24.
17. Sims JE, Gayle MA, Slack JL, Alderson MR, Bird TA, Giri JG, et al. Interleukin-1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci U S A 1993;90:6155-9.
18. Arend WP, Malyak M, Smith MF Jr, Whisenand TD, Slack JL, Sims JE, et al. Binding of IL-1 alpha. IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 1994;153:4766-74.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
20. Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjögren's syndrome in labial salivary gland biopsies. Oral Surg 1974;37:217-29.
21. Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. QJM 1968;37:393-406.
22. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
23. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol 1977;18:481-91.
24. Giri JG, Wells J, Dower SK, McCall CE, Guzman RN, Slack J, et al. Elevated levels of shed type II IL-1 receptor in sepsis: potential role for type II receptor in regulation of IL-1 responses. J Immunol 1994;153:5802-9.
25. Vannier E, Barak V, Fantuzzi G, Nisman B, Polliack A, Dinarello CA. Elevated levels of circulating soluble IL-1 receptor type II in hairy cell leukemia. Submitted for publication.
26. Poutsiaka DD, Clark BD, Vannier E, Dinarello CA. Production of interleukin-1 receptor antagonist and interleukin-1 β by peripheral blood mononuclear cells is differentially regulated. Blood 1991;78: 1275-81.
27. Van Zeben D, Hazes JMW, Zwinderman AH, Cats A, Schreuder GMT, D'Amaro J, et al. Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis: results of a followup study. Arthritis Rheum 1991;34:822-30.
28. Combe B, Eliaou JF, Daures JP, Meyer O, Clot J, Sany J. Prognostic factors in rheumatoid arthritis: comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol 1995;34:529-34.
29. Prieur AM, Kaufmann M-T, Griscelli C, Dayer J-M. Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet 1987;2:1240-2.
30. Miller LC, Lynch EA, Isa S, Logan JW, Dinarello CA, Steere AC. Balance of synovial fluid IL-1β and IL-1 receptor antagonist and recovery from Lyme arthritis. Lancet 1993;341:146-8.
31. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 1997;99:2930-40.
32. Hirsch E, Irikura VM, Paul SM, Hirsh D. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci U S A 1996;93:11008-13.
33. Eastgate JA, Wood NC, di Giovine FS, Symons JA, Grinlinton FM, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988;II:706-9.
34. Miossec P, Dinarello CA, Ziff M. Interleukin-1 lymphocyte chemotactic activity in rheumatoid arthritis synovial fluid. Arthritis Rheum 1986;29:461-70.
35. Jouvenne P, Fossiez F, Garonne P, Djossou O, Banchereau J, Miossec P. Increased incidence of neutralizing autoantibodies against IL-1 α in non-destructive chronic polyarthritis. J Clin Immunol 1996;16:283-90.
36. Drevlow BE, Lovis R, Haag MA, Sinacore JM, Jacobs C, Blosche C, et al. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1996;39:257-65.
37. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, and the IL-1Ra Arthritis Study Group. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1092-101.
38. Bresnihan B, Lookabaugh J, Witt K, Musikic P. Treatment with recombinant human interleukin-1 receptor antagonist in rheumatoid arthritis: results of a randomized, double-blind, placebo-controlled multicenter trial [abstract]. Arthritis Rheum 1996;39 Suppl 9:S73.
39. Watt I, Cobby M. Recombinant human interleukin-1 receptor antagonist reduces the rate of joint erosion in rheumatoid arthritis [abstract]. Arthritis Rheum 1996;39 Suppl 9:S123.
40. Vannier E, Miller LC, Dinarello CA. Coordinated anti-inflammatory effects of interleukin 4: IL-4 suppresses IL-1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci U S A 1992;89: 4076-80.
41. Vannier E, de Waal Malefyt R, Salazar Montes A, de Vries JE, Dinarello CA. Interleukin-13 (IL-13) induces IL-1 receptor antagonist gene expression and protein synthesis in peripheral blood mononuclear cells: inhibition by an IL-4 mutant protein. Blood 1996;87:3307-15.
42. Allen JB, Wong HL, Costa GL, Bienkowski MJ, Wahl SM. Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis. J Immunol 1993;151:4344-51.
43. Miossec P, Briolay J, Dechanet J, Wijdenes J, Martinez-Valdez H, Banchereau J. Interleukin 4 inhibits ex vivo production of proinflammatory cytokines and immunoglobulins by rheumatoid synovitis. Arthritis Rheum 1992;35:874-83.